THC BIOMED INTL LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.02 CAD | -.--% |
|
-.--% | -.--% |
Valuation
| Fiscal Period: Luglio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 40.26 | 127.8 | 29.04 | 31.69 | 17.2 | 7.377 |
| Enterprise Value (EV) 1 | 42.07 | 127.4 | 30.95 | 35.29 | 21.66 | 11.38 |
| P/E ratio | -65.9 x | -9.74 x | -1.98 x | -193 x | -2.7 x | -2.41 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 672 x | 138 x | 19.5 x | 7.58 x | 6.54 x | 3.01 x |
| EV / Revenue | 703 x | 138 x | 20.8 x | 8.45 x | 8.24 x | 4.65 x |
| EV / EBITDA | -29.2 x | -52.9 x | -7.26 x | 47.3 x | -3.93 x | -3.85 x |
| EV / FCF | 2,782 x | -14.2 x | -11.7 x | -12.9 x | 22.9 x | -15.3 x |
| FCF Yield | 0.04% | -7.02% | -8.54% | -7.74% | 4.36% | -6.54% |
| Price to Book | 20.3 x | 10.5 x | 2.16 x | 2.13 x | 1.76 x | 1.06 x |
| Nbr of stocks (in thousands) | 103,233 | 118,291 | 152,867 | 158,426 | 163,839 | 163,939 |
| Reference price 2 | 0.3900 | 1.080 | 0.1900 | 0.2000 | 0.1050 | 0.0450 |
| Announcement Date | 11/28/17 | 11/28/18 | 11/25/19 | 11/12/20 | 11/29/21 | 11/24/22 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Luglio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0599 | 0.9253 | 1.49 | 4.178 | 2.628 | 2.45 |
| EBITDA 1 | -1.441 | -2.408 | -4.263 | 0.7457 | -5.512 | -2.953 |
| EBIT 1 | -1.51 | -2.569 | -4.85 | -0.1301 | -6.335 | -3.66 |
| Operating Margin | -2,521.08% | -277.65% | -325.56% | -3.11% | -241% | -149.4% |
| Earnings before Tax (EBT) 1 | -0.6049 | -12.46 | -12.7 | -0.1616 | -6.359 | -3.066 |
| Net income 1 | -0.6049 | -12.46 | -12.7 | -0.1616 | -6.359 | -3.066 |
| Net margin | -1,010.2% | -1,346.42% | -852.53% | -3.87% | -241.94% | -125.15% |
| EPS 2 | -0.005921 | -0.1109 | -0.0958 | -0.001035 | -0.0389 | -0.0187 |
| Free Cash Flow 1 | 0.0151 | -8.942 | -2.644 | -2.73 | 0.9446 | -0.7447 |
| FCF margin | 25.26% | -966.34% | -177.48% | -65.33% | 35.94% | -30.4% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/28/17 | 11/28/18 | 11/25/19 | 11/12/20 | 11/29/21 | 11/24/22 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: July | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1.81 | - | 1.91 | 3.6 | 4.46 | 4 |
| Net Cash position 1 | - | 0.35 | - | - | - | - |
| Leverage (Debt/EBITDA) | -1.257 x | - | -0.4479 x | 4.833 x | -0.8093 x | -1.356 x |
| Free Cash Flow 1 | 0.02 | -8.94 | -2.64 | -2.73 | 0.94 | -0.74 |
| ROE (net income / shareholders' equity) | -51.9% | -176% | -98.9% | -1.14% | -51.6% | -36.7% |
| ROA (Net income/ Total Assets) | -22% | -15% | -18.6% | -0.41% | -20.2% | -14.2% |
| Assets 1 | 2.745 | 83.19 | 68.17 | 39.58 | 31.46 | 21.54 |
| Book Value Per Share 2 | 0.0200 | 0.1000 | 0.0900 | 0.0900 | 0.0600 | 0.0400 |
| Cash Flow per Share 2 | 0 | 0.0200 | 0.0100 | 0 | 0 | 0 |
| Capex 1 | 0.31 | 5.13 | 7.16 | 1.43 | 0.37 | 0.16 |
| Capex / Sales | 521.86% | 554.57% | 480.33% | 34.15% | 14.05% | 6.54% |
| Announcement Date | 11/28/17 | 11/28/18 | 11/25/19 | 11/12/20 | 11/29/21 | 11/24/22 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 2.4M | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.19B | |
| +3.98% | 3.15B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- THC Stock
- Financials THC Biomed Intl Ltd.